J 2022

Self-reported side effects of the Oxford AstraZeneca COVID-19 vaccine among healthcare workers in Ethiopia, Africa: A cross-sectional study

ALI, Yesuf Elias, Abanoub RIAD, Ahmad SOFI-MAHMUDI, Sudhakar MORANKAR, Mekonnen ADDISALEM et. al.

Základní údaje

Originální název

Self-reported side effects of the Oxford AstraZeneca COVID-19 vaccine among healthcare workers in Ethiopia, Africa: A cross-sectional study

Autoři

ALI, Yesuf Elias, Abanoub RIAD (818 Egypt, garant, domácí), Ahmad SOFI-MAHMUDI, Sudhakar MORANKAR, Mekonnen ADDISALEM, Endalkachew SELAMAWIT, Mama FEYISSA, Muhidin SEMIRA, Ayele BETHELHEM, Yahya MOHAMMED, Usman ABDUSELAM, Abafita JEMAL a Miloslav KLUGAR (203 Česká republika, domácí)

Vydání

Frontiers in Public Health, LAUSANNE, FRONTIERS MEDIA SA, 2022, 2296-2565

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30304 Public and environmental health

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 5.200

Kód RIV

RIV/00216224:14110/22:00126336

Organizační jednotka

Lékařská fakulta

UT WoS

000835095000001

Klíčová slova anglicky

Healthcare workers; COVID-19 vaccine; side effects; Oxford AstraZeneca; Ethiopia; Africa

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 5. 4. 2023 08:17, Mgr. Tereza Miškechová

Anotace

V originále

Introduction: Ethiopia is the second most populous country in Africa. Ethiopia received most of its COVID-19 vaccines through donations. The Oxford AstraZeneca vaccine is the first to be donated to Ethiopia by the COVAX facility. Healthcare workers were the priority population that received the Oxford AstraZeneca COVID-19 vaccine. However, there was no nationwide study on the safety of the vaccine in Ethiopia. This study aimed to measure the prevalence and predictors of self-reported side effects of the Oxford AstraZeneca vaccine. Materials and methods: The study employed a cross-sectional design. A sample of healthcare workers who took Oxford AstraZeneca COVID-19 vaccine was drawn from four regions of Ethiopia; namely, Amhara, Oromia, Somali, and Southwest. Data were collected on sociodemographic characteristics, medical anamnesis, COVID-19 related anamnesis, and COVID-19 vaccine anamnesis via telephone interview. Descriptive and inferential analyses were done. The software, IBM SPSS Statistics v21.0, was used for analyses of data. Results: Out of 384 people, 346 responded (response rate: 90.1%). Female accounted for 34.1% of the respondents. The mean age of the respondents was 31.0 years (Standard Deviation (SD) = 7.4). Nurses accounted for 43.7% of the respondents. The prevalence of at least one local- and systemic-side effect was 50.6 and 44.5%, respectively. The most frequent local- and systemic- side effect were injection site pain and headache, respectively. Both types of side effects mostly subsided in the first 3 days. A third of healthcare workers with side effects took at least one medication. Paracetamol followed by diclofenac sodium were taken by healthcare workers to overcome side effects. There was no independent predictor of local side effect. After controlling for age and chronic diseases, the odds of healthcare workers with COVID-19 like symptoms to experience systemic side effects was 1.38 (Confidence Interval (CI): 1.04–1.82) times more than that of healthcare workers without COVID-19 like symptoms. Conclusions: The prevalence of local- and systemic-side effects of the Oxford AstraZeneca COVID-19 vaccine was modest. As the symptoms were mostly common in the first 3 days, it is preferable to monitor healthcare workers at least in the first 3 days following the administration of the vaccine.

Návaznosti

EF19_073/0016943, projekt VaV
Název: Interní grantová agentura Masarykovy univerzity
LTC20031, projekt VaV
Název: Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic
Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic, INTER-COST
MUNI/IGA/1104/2021, interní kód MU
Název: COVID-19 Vaccines Safety Tracking in the Czech Republic (Akronym: CoVaST-CZ)
Investor: Masarykova univerzita, COVID-19 Vaccines Safety Tracking in the Czech Republic